id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_5pchiyh5fnfjdhthzgeusqriqq	Corrado Boni	Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases	2015	7	.pdf	application/pdf	4225	404	61	Pei regimen: a therapeutic option in small cell lung cancer? Objectives: Combination chemotherapy is very active in small cell lung cancer (SCLC), although no improvement in standard, with an average median survival of about 7–8 months in patients with extended disease (ED). In 1995, a randomized trial of the Hoosier Group in 171 ED patients showed a significant advantage in overall survival in patients treated with PEI (Cisplatin, Etoposide and Ifosfamide), compared to PE. Results: In 19 limited disease (LD) patients partial response (PR) rate was 74%, and complete response (CR) Keywords: Small cell lung cancer, Extended disease, Limited disease, Chemotherapy, Cisplatin, Etoposide, Between December 1998 and December 2008, 46 consecutive SCLC patients were treated in first line of chemotherapy with PEI regimen. The Hoosier Oncology Group study showed an improved time to progression (statistically different) and overall survival associated with PEI combination chemotherapy	./cache/work_5pchiyh5fnfjdhthzgeusqriqq.pdf	./txt/work_5pchiyh5fnfjdhthzgeusqriqq.txt